GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aclaris Therapeutics Inc (FRA:8AT) » Definitions » Short Percentage of Float

Aclaris Therapeutics (FRA:8AT) Short Percentage of Float


View and export this data going back to 2017. Start your Free Trial

What is Aclaris Therapeutics Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Aclaris Therapeutics's Short Percentage of Float

For the Biotechnology subindustry, Aclaris Therapeutics's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aclaris Therapeutics's Short Percentage of Float Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aclaris Therapeutics's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Aclaris Therapeutics's Short Percentage of Float falls into.


;
;

Aclaris Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aclaris Therapeutics Inc (FRA:8AT) » Definitions » Short Percentage of Float
Comparable Companies
LDDD XGN OCX MDXH BDSX FONR NOTV PRE ADVB MEHCQ TMO DHR XSWX:LONN IDXX A IQV SHSE:603259 MTD NTRA WAT
Traded in Other Exchanges
ACRS:USA 0H8T:UK
Address
701 Lee Road, Suite 103, Wayne, PA, USA, 19087
Website
https://www.aclaristx.com
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

Aclaris Therapeutics Headlines

No Headlines